2-Alkyl nicotinoids and processes for their production
申请人:Philip Morris Incorporated
公开号:US04155909A1
公开(公告)日:1979-05-22
The invention relates to 2-alkyl nicotinoids and improved methods for producing them.
本发明涉及2-烷基烟酰胺类化合物及其改进的制备方法。
Process for preparing 2-alkyl nicotinoids
申请人:Philip Morris, Inc.
公开号:US04220781A1
公开(公告)日:1980-09-02
The invention relates to 2-alkyl nicotinoids and improved methods for producing them.
本发明涉及2-烷基烟酰胺类化合物及其生产改进方法。
2-Alkyl nicotinoids and processes for their production and use
申请人:PHILIP MORRIS INCORPORATED
公开号:EP0000106A1
公开(公告)日:1978-12-20
2-Alkyl-nicotinoids represented by formula (I)
wherein R1 is hydrogen, lower alkyl, phenyl alkyl or aralkyl, R2 is lower alkyl or phenyl alkyl, and R3 is represented by the formula:
wherein R4 is hydrogen or lower alkyl, Rs is lower alkyl, and n is one or two, which are prepared according to the schema:
wherein X =chlorine,bromine,
iodine or
fluorine I
The compounds of formula (i) are useful as insecticides.
Patients suffering from neurodegenerative diseases are treated by administering an effective amount of certain anabasine compounds, certain unsaturated anabasine compounds or unsaturated nicotine compounds. Exemplary compounds are myosmine and anatabine.
A lozenge is provided that has stable pH and stable levels of active ingredient over time. It comprises a combination of (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol in a matrix designed for controlled buccal delivery of a drug. The lozenge also contains water and optional components selected from flavourings, taste masking agents, colourings, buffer components, pH adjusting agents, excipients, stabilizers and sweeteners. Methods of preparing the lozenge are also provided.